42 U.S.C. § 19134 — Advisory committee on engineering biology research and development

(a) In general: The agency co-chair of the interagency committee established under section 19133 must, working with the Office of Science and Technology Policy, designate or establish an advisory committee on engineering biology research and development (the "advisory committee"). It must have at least 12 members, including representatives of research and academic institutions, industry, and nongovernmental entities, who are qualified to advise on the Initiative. (b) Assessment: The advisory committee must assess: (1) the current state of U.S. competitiveness in engineering biology, including the scope and scale of U.S. investment compared internationally; (2) current market barriers to commercializing engineering biology products, processes, and tools in the U.S.; (3) progress made in implementing the Initiative; (4) the need to revise the Initiative; (5) the balance of activities and funding across the Initiative; (6) whether the strategic plan developed or updated by the interagency committee under section 19133 is helping maintain U.S. leadership in engineering biology; and (7) whether ethical, legal, environmental, safety, security, and other societal issues are adequately addressed by the Initiative. (c) Reports: Beginning not later than two years after August 9, 2022, and at least every five years after that, the advisory committee must submit to the President and listed House and Senate committees a report on: (1) the findings of its assessment under (b); and (2) its recommendations for improving the Initiative. (d) Application of Federal Advisory Committee Act: Section 14 of the Federal Advisory Committee Act — which covers annual reports and committee minutes — does not apply to the advisory committee. (e) Termination: The advisory committee ends 10 years after August 9, 2022.